FDA Grants Emergency Use Authorization for Boehringer Ingelheim’s Screwworm Treatments in Pets
Event summary
- FDA issued Emergency Use Authorizations for NexGard® Chewables and NexGard® COMBO to treat New World screwworm infestations in dogs and cats on February 19, 2026.
- New World screwworm cases confirmed in livestock in northern Mexico, near the Texas border, heightening U.S. preparedness concerns.
- NexGard and NexGard COMBO are authorized for veterinary use only and are not yet approved for this specific treatment.
- Boehringer Ingelheim emphasizes the importance of flea and tick control to prevent screwworm infestations.
The big picture
The FDA’s emergency authorization reflects growing concerns over the spread of New World screwworm from Mexico into the U.S., posing a significant threat to animal health. Boehringer Ingelheim’s strategic move to secure EUA for its existing products underscores the need for rapid response mechanisms in veterinary medicine. The authorization also highlights the broader trend of cross-border disease management and the importance of preventive healthcare in the pet industry.
What we're watching
- Regulatory Headwinds
- Whether the FDA’s emergency authorization will lead to broader approvals or face regulatory hurdles in the future.
- Market Dynamics
- How the spread of New World screwworm in Mexico will impact demand for Boehringer Ingelheim’s treatments in the U.S. pet market.
- Execution Risk
- The pace at which Boehringer Ingelheim can scale production and distribution of these treatments to meet potential demand.
Related topics